Bharat Immunologicals & Biologicals Corporation Ltd - Stock Valuation and Financial Performance

BSE: 524663 | NSE: | Pharmaceuticals & Drugs | Small Cap

Bharat Immunological Share Price

28.28 -0.42 -1.46%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Bharat Immunological

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Bharat Immunologicals & Biologicals Corporation stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
123.9 Cr.
52-wk low:
20.5
52-wk high:
43.9

Is Bharat Immunologicals & Biologicals Corporation Ltd an attractive stock to invest in?

1. Is Bharat Immunologicals & Biologicals Corporation Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bharat Immunologicals & Biologicals Corporation Ltd is a below average quality company.

2. Is Bharat Immunologicals & Biologicals Corporation Ltd undervalued or overvalued?

The key valuation ratios of Bharat Immunologicals & Biologicals Corporation Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Bharat Immunologicals & Biologicals Corporation Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bharat Immunologicals & Biologicals Corporation Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Bharat Immunological:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Bharat Immunologicals & Biologicals Corporation Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 21.6%9.1%-5.8%21.6%-9%-13.3%-16.1%-35.4%-4.2%-6.8%-
Value Creation
Index
0.6-0.4-1.40.6-1.6-2.0-2.2-3.5NANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 20314612812434.883.766.885.378.444.645
Sales YoY Gr.--27.9%-12.4%-3%-72%140.4%-20.1%27.7%-8.1%-43.1%-
Adj EPS 10.6-1.41.5-1-1.9-2.4-4.3-2.1-3.8-3.9
YoY Gr.--45.2%-352.6%NA-166.9%NANANANANA-
BVPS (₹) 9.29.68.19.78.77.14.70.6-1.5-5.3-7.5
Adj Net
Profit
4.52.5-6.26.4-4.3-8.1-10.3-18.4-9.1-16.5-17
Cash Flow from Ops. -11.97.8-9.4-172.5-32.134.111.8-42.110.9-
Debt/CF from Ops. 0.1-1.1-100-10.12.3-1.96.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -15.5%5.1%-12.6%-43.1%
Adj EPS -215.6%NANANA
BVPS-194.1%-190.7%-204%NA
Share Price 12.5% 31.1% -15.8% 33%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
116-16.316.6-10.8-23.7-40.3-67.4-13.1-17.159.8
Op. Profit
Mgn %
5.93.2-3.210.3-22.8-11.1-15.6-24.5-6.3-35.6-9.4
Net Profit
Mgn %
2.21.7-4.95.2-12.3-9.7-15.4-21.5-11.6-37-37.3
Debt to
Equity
-0-0.20.3001.10.211.6-12.2-3.10
Working Cap
Days
87130119741592675412852334100
Cash Conv.
Cycle
638554612515325053842090

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 59.80%

Sales growth has been subdued in last 3 years -12.61%

Sales growth is not so good in last 4 quarters at -73.20%

Latest Financials - Bharat Immunologicals & Biologicals Corporation Ltd.

Standalone Consolidated
TTM EPS (₹) -3.9 -
TTM Sales (₹ Cr.) 44.6 -
BVPS (₹.) -7.5 -
Reserves (₹ Cr.) -76 -
P/BV -3.81 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 20.50 / 43.89
All Time Low / High (₹) 0.25 / 94.50
Market Cap (₹ Cr.) 124
Equity (₹ Cr.) 43.2
Face Value (₹) 10
Industry PE 47.8

Management X-Ray of Bharat Immunological:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Bharat Immunological

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales203146128124358467857845
Operating Expenses 1911431321114393771068361
Manufacturing Costs171513104119985
Material Costs15311110690277156816039
Employee Cost 11101010101011141415
Other Costs 9732111122
Operating Profit 123-413-8-9-10-21-5-16
Operating Profit Margin (%) 5.9%2.3%-3.1%10.3%-22.8%-11.1%-15.6%-24.4%-6.3%-36.0%
Other Income 6111141211
Interest 6164125567
Depreciation 1111000000
Exceptional Items 0000000000
Profit Before Tax 112-99-8-7-14-24-10-22
Tax 51-33-4-2-4-6-1-6
Profit After Tax 62-67-4-6-10-18-9-17
PAT Margin (%) 3.2%1.1%-4.8%5.2%-12.2%-6.9%-15.3%-21.2%-11.2%-37.3%
Adjusted EPS (₹)1.50.4-1.41.5-1.0-1.3-2.4-4.2-2.0-3.9
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 404135423731203410588
Share Capital 43434343434343434343
Reserves -3-2-8-1-6-13-23-96245
Minority Interest0000000000
Debt-1-9900323277870
Long Term Debt0000000000
Short Term Debt-1-9900323277870
Trade Payables323180044441511
Others Liabilities 201714138846883
Total Liabilities 918066554511511384192162

Fixed Assets

Gross Block456456664646158157
Accumulated Depreciation3804011141414241
Net Fixed Assets76555544116116
CWIP 00000003200
Investments 0000000000
Inventories30262202145213361
Trade Receivables26141361673180114
Cash Equivalents 233020392081211139
Others Assets445331527242522
Total Assets 918066554511511384192162

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity -128-9-173-323412-4211
PBT 112-99-8-7-14-24-10-22
Adjustment 90150043656
Changes in Working Capital -326-2-3110-2544-0-3827
Tax Paid 0000000000
Cash Flow From Investing Activity 0010111110
Capex 0000000000
Net Investments 0000000000
Others 0111111110
Cash Flow From Financing Activity -6-1-2-3-331-34-1245-15
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid -6-1-2-3-1-2-5-5-6-7
Dividend Paid 0000000000
Others -1000-233-30-751-8
Net Cash Flow -187-10-201-1103-3
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)15.683.81-16.2516.94-10.76-17-39.93-158.6400
ROCE (%)42.299.07-8.5231.11-17.52-10.7-21.87-73.05-8.08-25.63
Asset Turnover Ratio2.311.711.752.060.71.040.590.870.570.25
PAT to CFO Conversion(x)-24N/A-2.43N/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days2550382911719424738361
Inventory Days566969341135181139116154
Payable Days8110467165115286131489

Bharat Immunologicals & Biologicals Corporation Ltd Stock News

Bharat Immunologicals & Biologicals Corporation Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Bharat Immunological on 28-Mar-2024 16:01 is ₹28.28.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Bharat Immunological stood at ₹123.9.
The latest P/E ratio of Bharat Immunological as of 28-Mar-2024 16:01 is 0.00.
The latest P/B ratio of Bharat Immunological as of 28-Mar-2024 16:01 is -3.81.
The 52-week high of Bharat Immunological is ₹43.89 and the 52-week low is ₹20.50.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Bharat Immunological is ₹44.61 ( Cr.) .

About Bharat Immunologicals & Biologicals Corporation Ltd

Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science & Technology, Government of India. BIBCOL was established as a Public Sector Unit in 1989, with the aim to achieve self sufficiency for the nation with respect to production and supply of high quality polio vaccine, a dream project of the Former Prime Minister Late Rajiv Gandhi.

BIBCOL’s principal mission is to save the lives of millions of children from avoidable disability, through polio vaccination. Since its inception, it has contributed significantly to the eradication of Poliomyelitis in the country through the National Immunization Program. BIBCOL is the pioneer in the field of polio vaccines, capturing 60% of total market share in India. The company has achieved a turnover of Rs.30.53 crores during the fiscal year 2005-2006 and earned a net profit of Rs.88.08 Lakhs. Based on the performance of the company and its world class WHO-cGMP certified infrastructure, highly skilled manpower and constant support from DBT, Government of India, BIBCOL is one among the top 20 Biotech companies in India, as revealed by recent market surveys.

Business area of the company:

The Company's principal activity is to manufacture and supply of oral polio vaccine. It supplies oral polio vaccine to Government of India. Its plant is located in Bulandshahr, Uttar Pradesh.

The live oral polio vaccine (OPV) is a trivalent vaccine containing suspensions of type 1,2 and 3 attenuated poliomyelitis viruses (Sabin strains) prepared in primary moneky kidney cell culture. Each dose contains Poliovirus type 1 = 106.0Poliovirus type 2 = 105.0Poliovirus type 3 = 105.8The vaccine contains stabilizers and traces of antibiotics.Doses: 0.1 ml (two drops)Packing Size: 3 ml vial contains 20 doses of OPVStorage: Vaccine is potent if stored at -20oC for 2 years

The trivalent OPV manufactured by BIBCOL is of excellent quality and complies with the GMP requirements of Shedule M of Drugs & Cosmetics Act of Government of India.

Milestones:

  • 1989 - BIBCOL was established by Department of Biotechnology, Ministry of Science & Technology, Govt.of India as a Central Public Sector Unit and incorporated under the Company’s Act 1956.
  • 1989 - About 30 young scientists and technologists from the field of Microbiology, Immunology, Biotechnology, Biochemistry, Pharmaceutical Sciences and Biochemical Engineering were recruited by DBT and trained in the field of vaccine production and quality control in reputed institutes in India and a specialized training at the Institute of Poliomyelitis and Viral Encephalitis, Moscow, Russia
  • 1994- BIBCOL went public and the shares of the company were listed in Delhi, Mumbai and Kanpur stock exchanges
  • 1996 -The company started formulating OPV from bulk since January 1996
  • 1999 - The company acquired WHO-GMP certification
  • 2000- BIBCOL bagged an order from UNICEF as well as from Ministry of Health and Family Welfare, Govt.of India for a total of 170 million doses
  • 2001 - The company bagged another larger order of 270 million doses from UNICEF as well as from the Ministry of Health & Family Welfare, Govt.of India
  • 2004- Due to the extensive restructuring with in the company, BIBCOL achieved a turn over of Rs.53.25 crore during the fiscal year 2004-2005 and has earned a net profit of 132.44 lacs for the first time against the loss pf Rs.3.14 crore during the previous fiscal year 2003-2004
  • 2005 -For the first time, the company has signed a MoU with DBT for the fiscal year 2005-2006. The OPV plant at Chola, Bulandshahr has supplied about 1016 million doses of OPV to the National Immunization Program so far. During the year 2004-2005, 120 million doses were formulated and supplied to NIP, capturing nearly 60 percent of the total market share of polio vaccines in the country.
  • 2006 - The company has secured a place among the Top 20 Biotech companies in the country through its commendable performance.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.